Please assess the completion status of the following clinical trial:

Trial Title: MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic kidney disease stage KDIGO 4 or 5~* First kidney transplant from a living donor~* Age ≥ 18 years~* ABO compatible~* CDC-PRA \< 20%~* No donor-specific antibodies~* Negative CDC and ELISA crossmatch~* Immunosuppression with cyclosporin A, EC-MPS and methylprednisolone~* Informed consent~* Adequate contraception (women with child bearing potential)~Exclusion Criteria:~* Psychiatric disorder~* Heart failure (NYHA III or IV)~* Severe liver disease~* Active hepatitis B or C or HIV infection~* Active bacterial, fungal or viral disease~* Malignancy or malignancy in the last 5 years before screening~* Preexisting immunosuppression~* Vaccination with a live vaccine in the last 3 months before screening~* S/p splenectomy~* Substance abuse~* Pregnancy or lactation~* Women: Child/pregnancy with the intended donor~* Allergy against the investigational drug or part of it~* Other diseases that prohibit participation in the study (in the opinion of the investigator)~* Participation in an other interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Patients receive MIC cell therapy together with standard immunosuppressive therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).